EUVIMEDSkopri EUVIMED
Klinische Studie (Phase IV)Multizentrische StudieRandomisierte kontrollierte StudieOpen access · CC BY 4.0

Application of the Lancet Commission Criteria for the Diagnosis of Obesity to a Clinical Trials Population: The LEAP Trial

Faith Anne N Heeren iD, Kathleen R Ruddiman iD, Courtney Simmons iD, Brian N White, Byron C Jaeger, Nicholas M Pajewski, Stephanie A Hooker iD, Deborah B Horn, Katy Martin-Fernandez, Kimberly A Gudzune iD, Caroline Blackwell Young, Jamy Ard and 1 more

Obesity · 2026-01 · 34 (1) · 58-64

DOI: 10.1002/oby.70070 ↗

At a glance

Klinische Studie (Phase IV) in Obesity, published online on 2025-10-27. Written by Faith Anne N Heeren and 12 co-authors. Institution: Department of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. Major MEDLINE topics: Obesity. Cited 7 times so far (Crossref); 21 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCATS NIH HHS, NHLBI NIH HHS, NCI NIH HHS.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Objective

This study aimed to apply The Lancet Diabetes & Endocrinology criteria for diagnosing obesity among clinical trial participants and understand participants' characteristics by obesity status.

Methods

The criteria were operationalized and applied to baseline data from the Long‐term Effectiveness of the Anti‐obesity medication Phentermine (LEAP) trial (NCT05176626). Excess adiposity, organ and tissue dysfunction, and limitations to daily activities were assessed. We examined differences between participants with “no obesity,” “pre‐clinical obesity,” and “clinical obesity.” Results Among the 860 participants, 0.8% had no obesity (mean BMI 29.0 kg/m 2 [SD 0.6]), 18.7% had pre‐clinical obesity (mean BMI 35.2 kg/m 2 [SD 3.5]), and 80.5% had clinical obesity (mean BMI 35.9 kg/m 2 [SD 4.3]). Participants with no/pre‐clinical obesity had lower mean SF‐12 mental component scores and greater baseline engagement with weight control strategies compared to those with clinical obesity. Participants with clinical obesity were older and, by definition, had a greater burden of cardiometabolic risk factors.

Conclusions

Among clinical trial participants eligible for obesity pharmacotherapy, 19.5% were classified as having no/pre‐clinical obesity using the Lancet criteria. Applying the criteria was complicated in a well‐resourced trial setting, which suggests potential challenges in implementing these guidelines in real‐world practice.

Subjects

MeSH terms (MEDLINE)

ObesityAdultAgedFemaleHumansMaleMiddle AgedAdiposityAnti-Obesity AgentsBody Mass IndexPhentermine

Author keywords

clinical carediagnosisobesity medicationobesity treatmentpharmacotherapy

Substances

Anti-Obesity AgentsPhentermine

Authors and institutions

  • Department of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Internal Medicine, Endocrinology Section, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • HealthPartners Institute, Minneapolis, Minnesota, USA.
  • Department of Family Medicine and Community Health, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Surgery, University of Texas McGovern Medical School, Houston, Texas, USA.

ORCID profiles: Faith Anne N Heeren, Kathleen R Ruddiman, Courtney Simmons, Stephanie A Hooker, Kimberly A Gudzune, Kristina Henderson Lewis

Funding

  • NCATS NIH HHS
  • NHLBI NIH HHS
  • NCI NIH HHS
  • National Heart, Lung, and Blood Institute

Cite

APA

Heeren, F. A. N., Ruddiman, K. R., Simmons, C., White, B. N., Jaeger, B. C., Pajewski, N. M., Hooker, S. A., Horn, D. B., Martin-Fernandez, K., Gudzune, K. A., Young, C. B., Ard, J., & Lewis, K. H. (2026). Application of the Lancet Commission Criteria for the Diagnosis of Obesity to a Clinical Trials Population: The LEAP Trial. Obesity, 34(1), 58-64. https://doi.org/10.1002/oby.70070

Vancouver

Heeren FAN, Ruddiman KR, Simmons C, White BN, Jaeger BC, Pajewski NM, et al. Application of the Lancet Commission Criteria for the Diagnosis of Obesity to a Clinical Trials Population: The LEAP Trial. Obesity. 2026;34(1):58-64. doi:10.1002/oby.70070

BibTeX
@article{Heeren2026,
  author = {Heeren, Faith Anne N and Ruddiman, Kathleen R and Simmons, Courtney and White, Brian N and Jaeger, Byron C and Pajewski, Nicholas M and Hooker, Stephanie A and Horn, Deborah B and Martin-Fernandez, Katy and Gudzune, Kimberly A and Young, Caroline Blackwell and Ard, Jamy and Lewis, Kristina Henderson},
  title = {Application of the Lancet Commission Criteria for the Diagnosis of Obesity to a Clinical Trials Population: The LEAP Trial},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {1},
  pages = {58--64},
  doi = {10.1002/oby.70070}
}
Start for free →